Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tri-Parametric Assessment of α-Galactosidase A Activity, lysoGb3 and X-Inactivation Aids Genotype-Phenotype Categorization of Fabry Disease Female Patients.

Journal of inherited metabolic disease·2026
Same author

Intersaphenous veins in a population with a high prevalence of chronic venous insufficiency.

Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft·2026
Same author

Long-term efficacy and safety of pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease: results from up to 5 years of the BRIGHT F51 phase III, open-label extension study.

Orphanet journal of rare diseases·2026
Same author

Evaluation of the severity of right-to-left shunt in patent foramen ovale patients after systemic embolism (MEASURE-PFO study).

Kardiologia polska·2026
Same author

Expert opinion on facilitating intrafamily communication in rare diseases-Lessons from Fabry disease.

Genetics in medicine open·2026
Same author

A non-coding signature in SHROOM3 is associated with kidney disease progression in Fabry disease.

Molecular genetics and metabolism·2026

Related Experiment Video

Updated: May 27, 2026

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

Does previous hypertension affect outcome in acute heart failure?

Marián Felšöci1, Jiří Pařenica, Jindřich Spinar

  • 11st Department of Internal Medicine - Cardiology, University Hospital Brno, Brno, Czech Republic.

European Journal of Internal Medicine
|November 15, 2011
PubMed
Summary

Previous hypertension is common in acute heart failure (HF) patients but doesn't independently affect mortality. Other factors like new-onset HF and body mass index are protective, while age, diabetes, and organ dysfunction worsen survival.

Related Experiment Videos

Last Updated: May 27, 2026

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

Area of Science:

  • Cardiology
  • Internal Medicine
  • Clinical Research

Background:

  • Previous long-term hypertension's impact on acute heart failure (HF) mortality is understudied.
  • Understanding this relationship is crucial for managing HF patients.

Purpose of the Study:

  • To investigate the effect of antecedent hypertension on mortality in acute heart failure patients.
  • To identify predictors of outcome in this population.

Main Methods:

  • Analysis of 2421 acute heart failure patients from the AHEAD registry.
  • Comparison of outcomes between patients with and without previous hypertension.
  • Multivariate analysis to identify independent predictors of mortality.

Main Results:

  • 71.5% of acute HF patients had previous hypertension; they were older, more often female, and had more comorbidities.
  • In-hospital mortality was similar, but 1-3 year survival was worse in hypertensive patients.
  • Hypertension was not an independent predictor of mortality; new-onset HF and higher BMI were protective, while age, diabetes, lower LVEF, and organ dysfunction predicted worse survival.

Conclusions:

  • Antecedent hypertension is prevalent in acute HF and contributes to organ damage.
  • Hypertension itself does not independently influence short- to medium-term mortality in acute HF.
  • Mortality is primarily driven by related comorbidities and clinical factors.